Shenzhen Hygia Biotechnology Co., Ltd.

Hygia Bio focuses on the research, development, production, and sales of new dietary supplement ingredients. In 2019, the company achieved the industrialization of high-purity nicotinamide mononucleotide (NMN) based on a new enzymatic method and owns a number of independent intellectual property rights. In the future, Hygia will introduce computer AI-design technology into the artificial assembly of proteins and combine it with new enzyme engineering technology to achieve more technological breakthroughs. In addition, Hygia Bio actively participates in the subject projects of domestic and foreign research institutions, helping to promote the research progress of NMN in clinical aspects, and continuously expanding the research on NMN application fields and related indications, providing more basic research data support for the NMN industry chain! Hygia Bio focuses on anti-aging, focuses on great health, and shares the future with you!